New AI-powered tools are being introduced by Google Cloud, holding the potential to revolutionize the drug development process for biotech and pharmaceutical companies.
Drug development takes a lot of crucial time costing treatment delivery to patients this is why Target and Lead Identification Suite and Multiomics Suite, leverage artificial intelligence to streamline crucial stages of drug development.
By harnessing the power of AI, Google Cloud intends to significantly reduce the time and cost associated with bringing new drugs to market.
The cannabis industry and biotechnology have been overlapping in the process of the development of new drugs. Google’s AI tools have the potential to transform business operations for companies operating at the intersection of biotech and cannabis. These tools could accelerate advancements in cannabis-related therapeutic treatments by expediting drug development processes and enabling more precise analysis of genetic data .
As the AI market continues to evolve, the integration of artificial intelligence into drug development is poised to revolutionize the healthcare and pharmaceutical industries, ultimately benefiting patients worldwide.
Recently at the Benzinga Cannabis Capital Conference, Würk CEO Scott Kenyon emphasized the need for companies to embrace technologies like AI to overcome challenges such as payroll and banking services and emphasized the potential of AI in HR processes as well.
(Click here to read more)